XNASCDIO
Market cap38mUSD
Jan 06, Last price
0.93USD
1D
9.38%
1Q
323.57%
IPO
-74.97%
Name
Cardio Diagnostics Holdings Inc
Chart & Performance
P/E
—
P/S
2,214.77
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
17k
+1,696.32%
Net income
-8m
L+79.72%
CFO
-6m
L+11.42%
Profile
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||
Revenues | 17 1,696.32% | 950 5.44% | ||
Cost of revenue | 7,240 | 4,549 | ||
Unusual Expense (Income) | ||||
NOPBT | (7,223) | (4,548) | ||
NOPBT Margin | ||||
Operating Taxes | 113 | |||
Tax Rate | ||||
NOPAT | (7,223) | (4,661) | ||
Net income | (8,377) 79.72% | (4,661) 651.23% | ||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 390 | 11,986 | ||
BB yield | -1.23% | -366.22% | ||
| Debt | ||||
Debt current | 598 | 849 | ||
Long-term debt | 1,550 | |||
Deferred revenue | ||||
Other long-term liabilities | ||||
Net debt | 865 | (3,268) | ||
| Cash flow | ||||
Cash from operating activities | (5,672) | (5,091) | ||
CAPEX | (576) | (76) | ||
Cash from investing activities | (794) | (368) | ||
Cash from financing activities | 3,632 | 9,064 | ||
FCF | (6,992) | (7,022) | ||
| Balance | ||||
Cash | 1,284 | 4,118 | ||
Long term investments | ||||
Excess cash | 1,283 | 4,117 | ||
Stockholders' equity | (14,368) | (5,991) | ||
Invested Capital | 18,587 | 13,090 | ||
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | 12,685 | 3,088 | ||
Price | 2.49 134.91% | 1.06 | ||
Market cap | 31,586 865.06% | 3,273 | ||
EV | 32,451 | 4 | ||
EBITDA | (7,112) | (4,532) | ||
EV/EBITDA | ||||
Interest | 6,735 | |||
Interest/NOPBT | ||||